MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/120/0.2/20.06.25 | Market Closed - Börse Stuttgart 02:49:37 2024-07-11 pm EDT | ||
| 5.78 EUR | -8.40% |
|
| Current month | -12.02% | ||
| 1 month | -10.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 5.78 | -8.40% |
| 24-07-10 | 6.31 | +4.64% |
| 24-07-09 | 6.03 | -6.66% |
| 24-07-08 | 6.46 | +2.54% |
| 24-07-05 | 6.3 | +4.30% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 02:49 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MB5BRS |
| ISIN | DE000MB5BRS5 |
| Date issued | 2023-04-05 |
| Strike | 120 $ |
| Maturity | 2025-06-20 (344 Days) |
| Parity | 5 : 1 |
| Emission price | 0.65 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.09 € |
|---|---|
| Lowest since issue | 0.4 € |
| Spread | 0.02 € |
| Spread % | 0.34% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.11%
- Stock Market
- Warrants
- Warrant
